Testing a diabetes prevention drug after kidney transplant
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a medicine called an SGLT2 inhibitor (which helps lower blood sugar) in people who have had a kidney transplant and do not have diabetes. The goal is to see if it can prevent new diabetes from developing after a transplant and help protect the transplanted kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have received a kidney transplant and are taking tacrolimus (an anti-rejection medicine)
- You do not currently have diabetes (type 1 or 2) and have not been treated for it
- Your kidney function is above a certain level (eGFR greater than 25)
- You are not pregnant, planning to become pregnant, or breastfeeding during the study
- You do not have any chronic inflammatory bowel disease (like Crohn's or ulcerative colitis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
Hear when a new Sodium Glucose Co-Transporter 2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.